Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre-Michel Llorca

Showing results (11-20 of 335) with videos related to

Pageof 34
Sort By:
La Revue Du Praticien|December 5, 2018
David Misdrahi, Guillaume Fond, Pierre-Michel Llorca
Therapeutic Advances in Chronic Disease|January 24, 2013
Asenapine in bipolar I disorder: evidence and place in patient managementLudovic Samalin, Thomas Charpeaud, Pierre-Michel Llorca
La Revue Du Praticien|December 5, 2018
David Misdrahi, Guillaume Fond, Pierre-Michel Llorca
Therapeutics and Clinical Risk Management|July 15, 2011
Clinical potential of lurasidone in the management of schizophreniaLudovic Samalin, Marion Garnier, Pierre-Michel Llorca
Presse Medicale (Paris, France : 1983)|May 21, 2005
[Systematic use in hospitals of a alcohol problems detecting questionnaire. The CAGE (cut down, annoyed, guilty, eye opener) questionnaire]Laurent Malet, Pierre-Michel Llorca, Michel Reynaud
Expert Review of Neurotherapeutics|August 7, 2014
Quetiapine extended release for the treatment of bipolar disorderLudovic Samalin, Aurore Tremey, Pierre-Michel Llorca
Acta Psychiatrica Scandinavica|June 26, 2024
Call for action to address premature mortality due to physical illness in individuals with severe mental disordersLaurent Boyer, Pierre-Michel Llorca, Guillaume Fond
L'Encephale|February 12, 2013
[Mixed states]Pierre-Michel Llorca, Thomas Charpeaud, Ludovic Samalin
Expert Review of Neurotherapeutics|February 1, 2024
Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adultsLudovic Samalin, Ludivine Boudieu, Pierre Michel Llorca
La Revue Du Praticien|February 8, 2024
[General principles for prescribing and monitoring psychotropic drugs]Marion Garnier, Pierre-Michel Llorca, Marie-Camille Patoz
Pageof 34

Showing results (11-20 of 335) with videos related to

Sort By:
Pageof 34
La Revue Du Praticien|December 5, 2018
David Misdrahi, Guillaume Fond, Pierre-Michel Llorca
Therapeutic Advances in Chronic Disease|January 24, 2013
Asenapine in bipolar I disorder: evidence and place in patient managementLudovic Samalin, Thomas Charpeaud, Pierre-Michel Llorca
La Revue Du Praticien|December 5, 2018
David Misdrahi, Guillaume Fond, Pierre-Michel Llorca
Therapeutics and Clinical Risk Management|July 15, 2011
Clinical potential of lurasidone in the management of schizophreniaLudovic Samalin, Marion Garnier, Pierre-Michel Llorca
Presse Medicale (Paris, France : 1983)|May 21, 2005
[Systematic use in hospitals of a alcohol problems detecting questionnaire. The CAGE (cut down, annoyed, guilty, eye opener) questionnaire]Laurent Malet, Pierre-Michel Llorca, Michel Reynaud
Expert Review of Neurotherapeutics|August 7, 2014
Quetiapine extended release for the treatment of bipolar disorderLudovic Samalin, Aurore Tremey, Pierre-Michel Llorca
Acta Psychiatrica Scandinavica|June 26, 2024
Call for action to address premature mortality due to physical illness in individuals with severe mental disordersLaurent Boyer, Pierre-Michel Llorca, Guillaume Fond
L'Encephale|February 12, 2013
[Mixed states]Pierre-Michel Llorca, Thomas Charpeaud, Ludovic Samalin
Expert Review of Neurotherapeutics|February 1, 2024
Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adultsLudovic Samalin, Ludivine Boudieu, Pierre Michel Llorca
La Revue Du Praticien|February 8, 2024
[General principles for prescribing and monitoring psychotropic drugs]Marion Garnier, Pierre-Michel Llorca, Marie-Camille Patoz
Pageof 34